KR102208283B1 - 인지증 치료제 또는 예방제 - Google Patents

인지증 치료제 또는 예방제 Download PDF

Info

Publication number
KR102208283B1
KR102208283B1 KR1020207007010A KR20207007010A KR102208283B1 KR 102208283 B1 KR102208283 B1 KR 102208283B1 KR 1020207007010 A KR1020207007010 A KR 1020207007010A KR 20207007010 A KR20207007010 A KR 20207007010A KR 102208283 B1 KR102208283 B1 KR 102208283B1
Authority
KR
South Korea
Prior art keywords
ser
gly
antibody
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007010A
Other languages
English (en)
Korean (ko)
Other versions
KR20200029619A (ko
Inventor
히로시 모리
다카미 도미야마
요이치 마츠모토
히로시 에구치
유이치 구노리
Original Assignee
고리쓰다이가쿠호진 오사카 시리쓰다이가쿠
데이진 화-마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠, 데이진 화-마 가부시키가이샤 filed Critical 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠
Publication of KR20200029619A publication Critical patent/KR20200029619A/ko
Application granted granted Critical
Publication of KR102208283B1 publication Critical patent/KR102208283B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207007010A 2012-05-31 2013-05-30 인지증 치료제 또는 예방제 Active KR102208283B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012124336 2012-05-31
JPJP-P-2012-124336 2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja) 2012-05-31 2013-05-30 認知症治療剤又は予防剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035417A Division KR102133610B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제

Publications (2)

Publication Number Publication Date
KR20200029619A KR20200029619A (ko) 2020-03-18
KR102208283B1 true KR102208283B1 (ko) 2021-01-26

Family

ID=49673425

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207007010A Active KR102208283B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제
KR1020147035417A Active KR102133610B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147035417A Active KR102133610B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제

Country Status (30)

Country Link
US (3) US20150183854A1 (enExample)
EP (2) EP2857039B1 (enExample)
JP (3) JP5971659B2 (enExample)
KR (2) KR102208283B1 (enExample)
CN (1) CN104602708B (enExample)
AR (1) AR091218A1 (enExample)
AU (2) AU2013268364B2 (enExample)
BR (1) BR112014029566A2 (enExample)
CA (1) CA2875205C (enExample)
CY (1) CY1122530T1 (enExample)
DK (1) DK2857039T3 (enExample)
ES (2) ES2973070T3 (enExample)
HR (1) HRP20192267T1 (enExample)
HU (1) HUE046919T2 (enExample)
IL (1) IL235899B (enExample)
LT (1) LT2857039T (enExample)
ME (1) ME03587B (enExample)
MX (1) MX361128B (enExample)
MY (1) MY172458A (enExample)
NZ (1) NZ630536A (enExample)
PH (1) PH12014502669B1 (enExample)
PL (1) PL2857039T3 (enExample)
PT (1) PT2857039T (enExample)
RS (1) RS59802B1 (enExample)
RU (1) RU2657438C2 (enExample)
SG (2) SG11201407878VA (enExample)
SI (1) SI2857039T1 (enExample)
TW (2) TWI777183B (enExample)
WO (1) WO2013180238A1 (enExample)
ZA (1) ZA201409186B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (en) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
MY172458A (en) * 2012-05-31 2019-11-26 Teijin Pharma Ltd Therapeutic agent or prophylactic agent for dementia
MY171473A (en) 2012-07-03 2019-10-15 Univ Washington Antibodies to tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP6785372B2 (ja) * 2016-09-30 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
CN110691794B (zh) 2017-05-30 2023-10-27 帝人制药株式会社 抗igf-i受体抗体
GEP20227406B (en) 2017-10-02 2022-08-25 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
WO2019077500A1 (en) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
JP7504026B2 (ja) 2018-04-06 2024-06-21 帝人ファーマ株式会社 Ｓｐｎｓ２中和抗体
JP7340794B2 (ja) * 2018-07-04 2023-09-08 学校法人 愛知医科大学 タウのスプライシングを制御するアンチセンスオリゴヌクレオチド及びその用途
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
JP7429404B2 (ja) * 2019-08-06 2024-02-08 慶應義塾 タウ関連疾患モデルの製造方法
JP7718270B2 (ja) 2019-09-30 2025-08-05 ニプロ株式会社 血液試料を検体とするタウタンパク質検出方法
EP4121071A4 (en) * 2020-03-19 2024-07-24 Vascular Biosciences PEPTIDE CAR FOR IMPROVED CORONAVIRUS SURVIVAL
BR112022026575A2 (pt) 2020-06-25 2023-01-17 Merck Sharp & Dohme Llc Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP2028932A4 (en) * 2006-06-16 2011-10-12 Vitruvean Llc TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2826286C (en) * 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
TR201102696U (tr) * 2011-05-27 2011-06-21 Turhal Sal�H Bağlantısız hareketli ürün reklam standı.
MY172458A (en) * 2012-05-31 2019-11-26 Teijin Pharma Ltd Therapeutic agent or prophylactic agent for dementia
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
JP2012530055A (ja) 2009-06-10 2012-11-29 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法

Also Published As

Publication number Publication date
JPWO2013180238A1 (ja) 2016-01-21
AR091218A1 (es) 2015-01-21
AU2018200413B2 (en) 2019-10-17
AU2013268364A1 (en) 2014-12-18
CN104602708A (zh) 2015-05-06
WO2013180238A1 (ja) 2013-12-05
JP6406678B2 (ja) 2018-10-17
HUE046919T2 (hu) 2020-04-28
LT2857039T (lt) 2020-03-10
TWI777183B (zh) 2022-09-11
US20220340646A1 (en) 2022-10-27
RU2014153099A (ru) 2016-07-20
MY172458A (en) 2019-11-26
RU2657438C2 (ru) 2018-06-13
HK1210031A1 (en) 2016-04-15
CY1122530T1 (el) 2021-01-27
EP2857039A4 (en) 2015-08-26
ES2763361T3 (es) 2020-05-28
PH12014502669B1 (en) 2020-02-19
MX361128B (es) 2018-11-28
NZ630536A (en) 2017-03-31
KR102133610B1 (ko) 2020-07-14
CA2875205C (en) 2021-07-20
SG11201407878VA (en) 2015-01-29
US20150183854A1 (en) 2015-07-02
EP3662931B1 (en) 2023-12-06
KR20150027098A (ko) 2015-03-11
TWI700296B (zh) 2020-08-01
PL2857039T3 (pl) 2020-05-18
AU2013268364B2 (en) 2018-02-08
AU2018200413A1 (en) 2018-02-08
PT2857039T (pt) 2020-01-07
US20200148753A1 (en) 2020-05-14
ZA201409186B (en) 2015-12-23
JP2018111716A (ja) 2018-07-19
CA2875205A1 (en) 2013-12-05
TW201410705A (zh) 2014-03-16
MX2014014187A (es) 2015-06-04
RS59802B1 (sr) 2020-02-28
EP2857039B1 (en) 2019-11-20
HRP20192267T1 (hr) 2020-03-20
BR112014029566A2 (pt) 2017-07-25
JP5971659B2 (ja) 2016-08-17
ME03587B (me) 2020-07-20
DK2857039T3 (da) 2019-12-16
KR20200029619A (ko) 2020-03-18
TW202041532A (zh) 2020-11-16
SI2857039T1 (sl) 2020-03-31
IL235899B (en) 2019-03-31
SG10201805410XA (en) 2018-08-30
EP3662931A1 (en) 2020-06-10
IL235899A0 (en) 2015-01-29
EP2857039A1 (en) 2015-04-08
JP2016147902A (ja) 2016-08-18
JP6620829B2 (ja) 2019-12-18
CN104602708B (zh) 2021-11-30
PH12014502669A1 (en) 2015-02-02
ES2973070T3 (es) 2024-06-18

Similar Documents

Publication Publication Date Title
KR102208283B1 (ko) 인지증 치료제 또는 예방제
JP7138322B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
JP2024026071A (ja) ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
KR20190098976A (ko) 타우 응집을 방지하기 위한 모노클로날 항-알파-시누클레인 항체
KR20160065981A (ko) 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TW202400643A (zh) 神經退化性疾病之治療劑
HK40031828B (en) Therapeutic agent or prophylactic agent for dementia
HK40031828A (en) Therapeutic agent or prophylactic agent for dementia
HK1210031B (zh) 痴呆症治疗药或预防药

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6